LON:COGCambridge Cognition Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cambridge Cognition Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 38 -1.00 (-2.56 %) (As of 07/6/2020 04:00 PM ET) Add Compare Share Today's Range 38Now: GBX 38▼ 39.5050-Day Range 24.50MA: GBX 29.42▼ 4252-Week Range 16.50Now: GBX 38▼ 72.38Volume31,502 shsAverage Volume40,421 shsMarket Capitalization£11.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesOptions Chain Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health products. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from phases I-IV or a cognitive testing software that enhances the chances of success and minimizing the risk of failure in neuroscience research; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and Cognitive health and wellbeing, which Optimize mental wellbeing and performance throughout the life. The company was incorporated in 2012 and is based in Cambridge, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cambridge Cognition. Previous Next 1.4 Community Rank Outperform VotesCambridge Cognition has received 105 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCambridge Cognition has received 264 “underperform” votes. (Add your “underperform” vote.)Community SentimentCambridge Cognition has received 71.54% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cambridge Cognition and other stocks. Vote “Outperform” if you believe COG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe COG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCambridge Cognition does not currently pay a dividend.Dividend GrowthCambridge Cognition does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cambridge Cognition insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cambridge Cognition is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cambridge Cognition is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.28 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:COG Previous Symbol CUSIPN/A CIKN/A Webwww.cambridgecognition.com Phone44 1223 810 700Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£5.04 million Price / Sales2.35 Cash FlowGBX 5.02 per share Price / Cash Flow7.57 Book ValueGBX (3.90) per share Price / Book-9.74Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees73 Outstanding Shares31,170,100Market Cap£11.84 million Next Earnings DateN/A OptionableOptionable LSE:COG Rates by TradingView Receive COG News and Ratings via Email Sign-up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter. Cambridge Cognition (LON:COG) Frequently Asked Questions How has Cambridge Cognition's stock been impacted by COVID-19 (Coronavirus)? Cambridge Cognition's stock was trading at GBX 20.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, COG shares have increased by 88.1% and is now trading at GBX 38. View which stocks have been most impacted by Coronavirus. How were Cambridge Cognition's earnings last quarter? Cambridge Cognition Holdings PLC (LON:COG) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($12.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($10.60) by $1.80. View Cambridge Cognition's earnings history. Has Cambridge Cognition been receiving favorable news coverage? News headlines about COG stock have trended negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cambridge Cognition earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Cambridge Cognition. Who are some of Cambridge Cognition's key competitors? Some companies that are related to Cambridge Cognition include BARD1 Life Sciences (BD1), Sernova (SVA), GeneNews (GEN), Imagion Biosys (IBX), LED Medical Diagnostics (LMD), Deepmatter Group (DMTR), Dorsavi (DVL), VentriPoint Diagnostics (VPT), Smiles Inclusive (SIL), Imaging Dynamics (IDL), Lifespot Health (LSH), Cryosite (CTE), 3D Signatures (DXD), Med Biogene (MBI) and Arch Capital Group (AWH). View all competitors. What other stocks do shareholders of Cambridge Cognition own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold (ALO), Concepta (CPT), European Metals (EMH), IntelGenx Technologies (IGXT), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT), Altyn (ALTN) and American International Group (AIG). Who are Cambridge Cognition's key executives? Cambridge Cognition's management team includes the following people: Dr. Steven John Powell, CEO & Director (Age 58)Mr. Nicholas John Cordeaux Walters, CFO, Sec. & Director (Age 61)Mr. John Hammond, Co-FounderDr. Matthew Stork, Chief Operating OfficerMr. Nick Taptiklis, Head of Technology Strategy What is Cambridge Cognition's stock symbol? Cambridge Cognition trades on the London Stock Exchange (LON) under the ticker symbol "COG." How do I buy shares of Cambridge Cognition? Shares of COG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Cambridge Cognition's stock price today? One share of COG stock can currently be purchased for approximately GBX 38. How big of a company is Cambridge Cognition? Cambridge Cognition has a market capitalization of £11.84 million and generates £5.04 million in revenue each year. Cambridge Cognition employs 73 workers across the globe. What is Cambridge Cognition's official website? The official website for Cambridge Cognition is www.cambridgecognition.com. How can I contact Cambridge Cognition? Cambridge Cognition's mailing address is Tunbridge Court Tunbridge Lane, Bottisham, CAMBRIDGE, CB25 9TU, United Kingdom. The company can be reached via phone at 44 1223 810 700. This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
